Sees low double digit revenue CAGR ex-Rev/Pom from 2020-2025. Sees $8B-$10B growth from in-line brands from 2020-2025. Sees more than $10B revenue from new product portfolio in 2026. Sees operating margin target more than 37% through 2025. Sees $25B NRA for nine new product portfolio in 2030. Comments taken from investor presentation slides.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY:
- The biopharmaceuticals stocks to own in 2024, according to BofA
- Bristol Myers downgraded to Neutral at BofA as more clarity on execution awaited
- Bristol Myers downgraded to Neutral from Buy at BofA
- Bristol Myers’ repotrectinib application validated by EMA
- Edgewise shares still reflect limited credit for EDG-7500, says Wedbush